The Food and Drug Administration (FDA) has approved Trulicity (dulaglutide; Eli Lilly) pen as adjunct to diet and exercise to improve glycemic control in in adults with type 2 diabetes. Dulaglutide, a ...

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

Trulicity Pen Now Available for Type 2 Diabetes Eli Lilly announced the launch of Trulicity (dulaglutide) pen indicated as adjunct to diet and exercise to ipmrove glycemic control in adults with type ...

-- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

Trulicity is a prescription drug used to help manage blood sugar levels and lower the risk of heart problems in certain adults. It is available as a liquid solution in prefilled injection pens.

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...